Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas.

Trial Profile

Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Astrocytoma; Glioma; Neurofibromatoses
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2016 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 26 Apr 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
    • 26 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top